Biogen (BIIB) PT Raised to $320 at Oppenheimer
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $210.78 +0.91%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 18 | Down: 15 | New: 9
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 18 | Down: 15 | New: 9
Join SI Premium – FREE
Oppenheimer analyst Jay Olson raised the price target on Biogen (NASDAQ: BIIB) to $320.00 (from $315.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- Asia Vital Components Co Ltd (3017:TT) PT Raised to NT$4,250 at Macquarie
- Medipal Holdings Corp (7459:JP) PT Lowered to JPY3,080 at Nomura/Instinet
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
